ArticleThe Eurasian journal of medicine2025
Pre-trained Artificial Intelligence Models in the Prediction and Classification of Atherosclerotic Cardiovascular Disease.
Article in The Eurasian journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes of global morbidity and mortality. The current study provides a systematic review of the use of artificial intelligence (AI) technologies applied to the prediction and management of ASCVD. Traditional risk assessment approaches have their restrictions, leading to a growing preference for AI and machine learning techniques in risk assessment. First, this study tackles the complex pathophysiology of ASCVD and the problems associated with the current diagnosis, followed by an in-depth analysis of the wide variety of AI models that can be applied to electronic health records, medical imaging data, and other biomarkers. Special attention will be paid toward the potential of natural language processing models like bidirectional encoder representations from transformers in predicting risk from textual clinical data, and the overwhelming success of convolutional neural networks such as residual neural network and visual geometry group in plaque-based analysis through imaging modalities. Although the research results show that these models have a lot to offer in the clinical world, the authors also describe some serious disadvantages: data bias, interpretability of the model, and computational needs. It highlights, in particular, the need for multicenter validation studies as well as developing explainable AI techniques. Overall, AI-based approaches may pave the way for a new paradigm in ASCVD management. Nevertheless, deploying these technologies in everyday clinical practice will require overcoming technical, ethical, and regulatory challenges. As such, interdisciplinary collaboration and thorough clinical validation studies are essential for fulfilling the promise of these novel strategies to enhance patient outcomes. Cite this article as: Şakiroğlu F, Çolak C, Çolak MC. Pre-trained artificial intelligence models in the prediction and classification of atherosclerotic cardiovascular disease. Eurasian J Med. 2025, 57(3), 0937, doi:10.5152/eurasianjmed.2025.25937.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.